WO2022153250 - PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY
National phase entry:
Publication Number
WO/2022/153250
Publication Date
21.07.2022
International Application No.
PCT/IB2022/050316
International Filing Date
14.01.2022
Title **
[English]
PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY
[French]
PROTOCOLE POUR RÉDUIRE AU MINIMUM LA NÉPHROTOXICITÉ D'UN INHIBITEUR DE CALCINEURINE
Applicants **
AURINIA PHARMACEUTICALS INC.
1203 - 4464 Markham Street
Victoria, British Columbia V8Z 7X8, CA
Inventors
MARTIN, Michael
1203 - 4464 Markham Street
Victoria, British Columbia V8Z 7X8, CA
HUIZINGA, Robert B.
1203 - 4464 Markham Street
Victoria, British Columbia V8Z 7X8, CA
SOLOMONS, Neil
1203 - 4464 Markham Street
Victoria, British Columbia V8Z 7X8, CA
Priority Data
63/138,325
15.01.2021
US
63/245,779
17.09.2021
US
63/246,765
21.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 747 | |
| EPO | Filing, Examination | 7239 | |
| Japan | Filing | 503 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 1910 |
Total: 11006 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are methods of employing pharmacodynamics regimens to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects, such as but not limited to calcineurin inhibitor nephrotoxicity. Also provided are methods of assessments of renal functions and/or conditions, and corresponding protocols to modify, stop, restore and/or re-initiate voclosporin dosing and administrations to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects.[French]
La présente invention concerne des procédés d'utilisation de régimes pharmacodynamiques pour maximiser l'efficacité de la voclostaurosporine dans le traitement de maladies rénales protéinuriques tout en réduisant au minimum les effets secondaires indésirables, tels que, mais sans y être limités, la néphrotoxicité d'un inhibiteur de calcineurine. L'invention concerne en outre des procédés d'évaluation de fonctions et/ou d'affections rénales, et des protocoles correspondants pour modifier, arrêter, restaurer et/ou réinstaurer la posologie et les administrations de voclosporine pour maximiser l'efficacité de la voclosporine dans le traitement de maladies rénales protéinuriques tout en réduisant au minimum les effets secondaires indésirables.